Hospital
Appalachian Regional Healthcare, INC.
Appalachian Regional Healthcare, INC. was paid $6.20M by Medicaid between Jan 2018 and Dec 2024, across 104 billing codes. Its largest line is 99284, emergency room visit (serious) — 10% of everything it billed.
33Billing provider infoAPPALACHIAN REGIONAL HEALTHCARE, INC.
HINTON, WV 25951
HINTON, WV 25951
33aNPI1689664179assigned 10/26/2005
33bProvider typeCritical Access Hospital
28Total paid$6.20M
24GClaims138,323
24DCodes billed104
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in West Virginia
Rank by total paid#11 of 24
Median peer was paid$3.57M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,987 | $1.47M | |
| 2019 | 13,919 | $654K | |
| 2020 | 29,151 | $1.66M | |
| 2021 | 29,144 | $1.22M | |
| 2022 | 13,157 | $437K | |
| 2023 | 11,839 | $458K | |
| 2024incomplete | 8,126 | $299K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 4,065 | 3,584 | $649K |
| 80053 | Comprehensive metabolic panel | 8.6% | 14,336 | 11,696 | $535K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.5% | 4,834 | 4,280 | $402K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.3% | 758 | 634 | $392K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.7% | 16,325 | 12,781 | $356K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 1,767 | 1,457 | $307K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.4% | 4,479 | 3,122 | $213K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 777 | 650 | $197K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.2% | 4,826 | 4,438 | $196K |
| 80061 | Lipid panel | 3.1% | 3,693 | 3,392 | $191K |
| 36415 | Collection of venous blood by venipuncture | 3.0% | 13,189 | 9,402 | $185K |
| 84484 | 2.1% | 3,806 | 2,547 | $130K |
92 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.9% | 2,030 | $118K |
| 71046 | Radiologic examination, chest; 2 views | 1.9% | 2,158 | $116K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 2,054 | $115K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 2,527 | $93K |
| 81001 | 1.5% | 4,236 | $92K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 1,109 | $89K |
| 83735 | 1.4% | 3,130 | $85K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 1,238 | $83K |
| 82150 | 1.3% | 1,065 | $80K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,278 | $80K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 2,474 | $78K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 2,841 | $73K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.2% | 3,350 | $72K |
| 82553 | 1.1% | 1,927 | $70K | |
| G0378 | Hospital observation service, per hour | <1% | 443 | $60K |
| 87040 | <1% | 861 | $55K | |
| 97035 | <1% | 1,245 | $53K | |
| 83690 | <1% | 1,170 | $51K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,864 | $50K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,198 | $49K |
| 83880 | <1% | 1,346 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,700 | $47K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 123 | $46K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,485 | $42K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,083 | $41K |
| 82550 | <1% | 1,656 | $41K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 605 | $41K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 966 | $39K |
| 72100 | <1% | 574 | $39K | |
| 83605 | <1% | 907 | $35K | |
| 85730 | <1% | 560 | $30K | |
| 85610 | <1% | 930 | $26K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 28 | $25K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 264 | $23K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 392 | $23K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,957 | $21K |
| 82607 | <1% | 364 | $18K | |
| 84703 | <1% | 384 | $17K | |
| 93041 | <1% | 870 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 522 | $17K |
| 73030 | <1% | 229 | $16K | |
| 99218 | <1% | 32 | $16K | |
| 73564 | <1% | 167 | $15K | |
| 87186 | <1% | 255 | $13K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 404 | $13K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 19 | $12K |
| 84439 | <1% | 261 | $11K | |
| 73630 | <1% | 150 | $9K | |
| 81025 | <1% | 233 | $9K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 444 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 567 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 291 | $8K |
| 87077 | <1% | 169 | $8K | |
| 97162 | <1% | 150 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,517 | $7K |
| 93017 | <1% | 19 | $6K | |
| 97014 | <1% | 129 | $5K | |
| 74018 | <1% | 93 | $5K | |
| 87076 | <1% | 190 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 112 | $4K |
| 82803 | <1% | 73 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 439 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 152 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 177 | $3K |
| 81002 | <1% | 176 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 19 | $3K |
| 82565 | <1% | 152 | $3K | |
| A9270 | Non-covered item or service | <1% | 763 | $3K |
| 84145 | <1% | 100 | $3K | |
| 36600 | <1% | 90 | $3K | |
| 73610 | <1% | 44 | $2K | |
| 85378 | <1% | 157 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 77 | $2K |
| 96376 | <1% | 79 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 109 | $2K |
| 80051 | <1% | 61 | $2K | |
| 85652 | <1% | 61 | $2K | |
| 73130 | <1% | 31 | $2K | |
| 82746 | <1% | 24 | $2K | |
| 84520 | <1% | 83 | $1K | |
| 94760 | <1% | 79 | $1K | |
| 85379 | <1% | 17 | $1K | |
| 87449 | <1% | 16 | $1K | |
| 86038 | <1% | 14 | $1K | |
| 84481 | <1% | 12 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14 | $915.50 |
| 84550 | <1% | 13 | $806.57 | |
| 87631 | <1% | 12 | $754.77 | |
| 87070 | <1% | 16 | $732.80 | |
| 86200 | <1% | 14 | $495.18 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 35 | $371.53 |
| 84153 | <1% | 14 | $335.36 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.